| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 3,850 | 3,380 | 2,820 | 2,410 | 3,290 |
| Sales Growth | +13.91% | +19.86% | +17.01% | -26.75% | -39.96% |
| Net Income | -1,950 | -2,080 | -1,140 | -2,330 | -1,750 |
| Net Income Growth | +6.25% | -82.46% | +51.07% | -33.14% | -195.63% |
Emmaus Life Sciences Inc (EMMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States.
Fiscal Year End Date: 12/31